PharmaDeals Review: Latest Articles
All the latest analysis of deal-making activity in the pharmaceutical and biotechnology sector provided by the experts from the PharmaDeals Review.
- Published on: 2008-08-15 Cytos Signs Vaccines Deal with Pfizer Cytos Biotechnology has entered into an exclusive agreement with Pfizer to research, develop, manufacture and commercialise novel vaccines for a defined number of human diseases. For Cytos, the deal could be worth up to US$137 M.
- Published on: 2008-08-12 CSL Seeks to Solidfy its Position by Acquiring Talecris CSL has agreed to buy Talecris Biotherapeutics for US$3.1 B and will be hoping that the acquisition will be passed by the competition regulators. If it goes through, CSL will strengthen its position in the global plasma market just behind the leader, Baxter International.
- Published on: 2008-08-08 Archemix in Yet Another Deal for its Aptamer Technology Archemix’s expertise and extensive IP portfolio, associated with the discovery and development of aptamers, has resulted in its latest agreement with the Japanese company, Ribomic. The license to access certain rights from Archemix’s IP portfolio is non-exclusive, but Ribomic has the option to convert it to an exclusive license for a particular target subject to a fee.
- Published on: 2008-08-06 The Medicines Company Acquires Curacyte and its Lead Antithrombotic Curacyte AG sold its subsidiary, Curacyte Discovery and its lead compound to The Medicines Company. CU-2010 is in preclinical development for surgical blood loss and could address an urgent medical need following the withdrawal of Bayer's antifibronolytic, aprotinin.
- Published on: 2008-08-06 Eli Lilly’s Novel Financing Approach to R&D Eli Lilly has entered into a number of interesting agreements to reduce costs and increase productivity – one of which is with Covance. The pharmaceutical industry is increasingly outsourcing key functions to reduce costs and speed up drug development times and companies like Aventis and Amgen have both made similar moves with Quintiles in the past.
- Published on: 2008-08-04 Valeant Pharmaceuticals’ De-Globalisation Strategy Sees the Sale of European Operations Valeant Pharmaceuticals sold its Western and Eastern European pharmaceutical business to Meda, giving Meda an opportunity to enter the Russian market. For Valeant, this is one of many agreements signed to achieve its goal of reducing its worldwide operations.
- Published on: 2008-08-01 Negotiations Begin Between Bristol-Myers Squibb and ImClone Bristol-Myers Squibb has offered to buy the remaining shares of ImClone for US$4.3B in cash. If the deal is successful, not only will it launch Bristol-Myers Squibb back into oncology since its loss of Taxol® to generic competition in 2001, but could also make the company ripe for acquisition itself.
- Published on: 2008-07-30 Mitsubishi Tanabe Builds its Presence in North America In its quest to expand its overseas operations in the field of chronic kidney disease, Mitsubishi Tanabe licensed Cytochroma’s vitamin D analogue, CTA018 , and acquired a stake in the Canadian company.
- Published on: 2008-07-25 Sanofi-Aventis Expands its Vaccine Portfolio Sanofi-Aventis has bought the British vaccine company, Acambis, for £276 M, in a deal that will beef up the French company’s vaccine portfolio. The move was not unexpected as the two companies already have a number of ongoing collaborations.
- Published on: 2008-07-22 BioMarin Licenses Summit’s Muscular Dystrophy Programme BioMarin Pharmaceutical and Summit Corporation plc entered into an exclusive worldwide licensing agreement for Summit’s preclinical candidate, SMT C1100, and all follow-on molecules for the treatment of Duchenne muscular dystrophy.
Last Issue PDF
RSS